Catestatin
Cardiovascular / Anti-HypertensiveAlso known as: Chromogranin A Fragment, CST, hCgA352-372
Mechanism
A natural peptide fragment released from the adrenal glands that acts as an internal brake on stress hormones. It blocks the release of adrenaline and noradrenaline, helping to lower blood pressure and protect the heart. People with essential hypertension have been found to have lower levels of catestatin, suggesting it plays an important role in blood pressure regulation.
Technical detail
21-amino-acid endogenous peptide (human sequence: SSMKLSFRARAYGFRGPGPQL) derived from proteolytic cleavage of chromogranin A (CgA, residues 352-372). Functions as an endogenous nicotinic cholinergic antagonist at the neuronal-type nicotinic acetylcholine receptor (nAChR) on adrenal chromaffin cells and sympathetic neurons, inhibiting catecholamine release in a non-competitive manner. Also exhibits direct vasodilatory effects via histamine H1 receptor-mediated NO release from endothelium. Demonstrates antimicrobial activity against skin pathogens. Plasma catestatin levels are reduced in essential hypertension patients and their normotensive offspring, serving as a heritable intermediate phenotype for hypertension risk.
Effects
CARDIOVASCULAR SYSTEM: Potent antihypertensive — catestatin inhibits nicotinic acetylcholine receptor-mediated catecholamine release from chromaffin cells and sympathetic neurons, reducing norepinephrine and epinephrine output [in vitro, animal]. Reduces blood pressure in hypertensive animal models without affecting normotensive animals (physiological specificity) [animal]. Vasodilatory effects via stimulation of histamine release from mast cells (H1 receptor-mediated vasodilation) and direct endothelial nitric oxide production [animal, in vitro]. Cardioprotective during ischemia-reperfusion injury — reduces infarct size and improves cardiac function in rodent models via PI3K/Akt and NO/cGMP signaling [animal]. Inhibits cardiac fibrosis and hypertrophy in pressure-overload models [animal]. BIOMARKER POTENTIAL: Plasma catestatin levels are significantly reduced in essential hypertension — inverse correlation with blood pressure severity [clinical studies — O'Connor et al., 2002, 2008]. Low catestatin levels predict future development of hypertension in normotensive individuals (prospective data) [clinical]. Reduced in heart failure patients, correlating with disease severity [clinical]. Potential biomarker for sympathetic nervous system activity and cardiovascular risk stratification [clinical]. ANTIMICROBIAL: Broad-spectrum antimicrobial activity against S. aureus, P. aeruginosa, and C. albicans via membrane disruption — catestatin is a cationic antimicrobial peptide in addition to its cardiovascular role [in vitro]. METABOLIC: Anti-obesity effects in animal models — reduces hepatic fatty acid synthesis and inflammation [animal]. Improves insulin sensitivity and glucose tolerance in diet-induced obese mice [animal]. IMMUNE/INFLAMMATORY: Anti-inflammatory — suppresses macrophage-mediated inflammation, reduces TNF-α and IL-6 production [in vitro, animal]. Promotes wound healing via stimulation of angiogenesis and keratinocyte migration [animal].
Practitioner Guide
CLINICAL CONTEXT: Catestatin is NOT available as a therapeutic agent. It is an endogenous peptide (chromogranin A fragment, amino acids 352-372) being studied as both a biomarker and potential therapeutic target. No compounding pharmacies produce it. Clinical relevance is currently limited to understanding its biology and biomarker potential. BIOMARKER USE: Chromogranin A (CgA) blood testing is commercially available and used as a surrogate — elevated CgA in pheochromocytoma, neuroendocrine tumors, and carcinoid; CgA processing to catestatin may be impaired in hypertension. However, CgA is not the same as catestatin, and specific catestatin assays are research-only. SUPPORTING ENDOGENOUS CATESTATIN: Since catestatin is a chromogranin A fragment, strategies to support its production are indirect: stress management (chronic sympathetic activation depletes CgA stores), regular aerobic exercise (improves autonomic balance), adequate sleep (7-8h — sympathetic tone regulation), magnesium supplementation (300-600mg/day — modulates catecholamine release), and omega-3 fatty acids (2-3g/day — autonomic function support). TRANSLATIONAL GAP: The main barrier to therapeutic catestatin is delivery — it is a peptide that requires injection, has a short half-life in plasma (minutes), and the therapeutic dose in humans is unknown. No pharmaceutical company has advanced it to clinical trials as a therapeutic. The biomarker application is closer to clinical translation. HYPERTENSION MANAGEMENT: For patients with hypertension, catestatin biology supports the importance of sympatholytic approaches — meditation/mindfulness, deep breathing, adequate sleep, exercise, and stress reduction as adjuncts to standard antihypertensive therapy. GENETIC CONSIDERATIONS: Catestatin has known functional polymorphisms (Gly364Ser) that affect antimicrobial activity and cardiovascular risk — pharmacogenomic relevance for future personalized medicine.
Research Summary
TIER 1: Clinical studies demonstrating reduced plasma catestatin in essential hypertension (O'Connor et al., 2002 — original characterization; O'Connor et al., 2008 — prospective data). Clinical data showing catestatin as predictor of future hypertension development. No RCTs of exogenous catestatin administration in humans. TIER 2: Comprehensive reviews of catestatin biology and cardiovascular effects (Mahata et al., 2010, 2018). Animal study reviews showing cardioprotective, antihypertensive, and anti-obesity effects. Reviews of chromogranin A-derived peptides as a family. Structural and functional analysis of catestatin variants. TIER 3: Limited clinical case data. Research group observations from the UCSD chromogranin A program (Mahata, O'Connor). International data from Italian cardiovascular cohorts measuring catestatin levels. KEY FINDINGS: Catestatin is a genuinely promising cardiovascular biomarker with robust clinical correlation data. The biology is compelling — a natural sympatholytic peptide that reduces catecholamine release. However, the translational gap is wide — no therapeutic development has reached clinical trials. It exemplifies a common pattern in peptide biology: great biomarker, challenging therapeutic. GAPS: No human dosing data. Pharmacokinetics in humans unknown. No clinical trials as therapeutic agent. Uncertain whether exogenous catestatin can replicate the effects of endogenous production. Half-life stabilization strategies not developed. ACTIVE TRIALS: Primarily observational — studies measuring catestatin as biomarker in heart failure, metabolic syndrome, and hypertension cohorts. No interventional trials with catestatin administration.